Official HCP Website | VUMERITY® (diroximel fumarate)
VUMERITY
The European Commission Grants Marketing Authorization for VUMERITY® (Diroximel Fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis. – News & Updates
Barry Singer MD 🧠 on Twitter: "#Vumerity Great news! New oral disease-modifying medication for #MS @US_FDA approved. Vumerity is converted in the body to monomethyl fumarate, same pathway as #Tecfidera. Glad to
Vumerity, INN-diroximel fumarate
Vumerity: Package Insert - Drugs.com
Switching Study | VUMERITY® (diroximel fumarate)
VUMERITY HCP Program Invitation | VUM-US-0381
Vumerity: Package Insert - Drugs.com
Vumerity: Side effects, alternatives, dosage, cost, and more
PML Foundation
diroximel fumarate (Vumerity®) RMP Summary
Vumerity (Diroximel Fumarate) in MS | Uses, Side Effects, and More | Multiple Sclerosis News Today
CHECKING IN
Real-World Studies | VUMERITY® (diroximel fumarate)
Multiple Sclerosis 101: Understanding PML and the JC Virus
Biogen Presents Update on its MS Therapeutic Portfolio
Australian Public Assessment Report for Vumerity
Start VUMERITY® (diroximel fumarate)
Vumerity, INN-diroximel fumarate
Vumerity: Side effects, alternatives, dosage, cost, and more
Brain Lesion Activity | VUMERITY® (diroximel fumarate)
Vumerity, INN-diroximel fumarate
Real-World Studies | VUMERITY® (diroximel fumarate)
DMT Information | IOMSN
